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Abstract 
Objective: To assess non-self-sufficiency (NSS) in ALS as an outcome measure in therapeutic 
trials. Methods: Using data from the control arm of two randomized trials and an observational 
study, NSS (score 2 or less in the ALS-FRS-R items for swallowing, cutting food and handling 
utensils, or walking) was compared to the total ALS-FRS-R score, forced vital capacity (FVC), and 
survival at selected time points until death or 48 weeks. Results: Of 82 self-sufficient (SS) patients 
at baseline, 32 (39.0%) became NSS at 4 weeks and 72 (87.8%) at the end of follow-up. A 
significant association was found between NSS, ALSFRS-R score and FVC at 24, 36, 48 weeks. 34 
subjects died (41.5%). As compared to SS patients (median survival, 27.9 months), individuals 
becoming NSS at 4 weeks were at increased risk to die during follow-up (median survival, 23.6 
months, p=0.02). NSS status at 4 weeks predicted survival even after adjustment for ALS-FRS-R 
total score, age, sex, site of onset, BMI, and FVC.“Walking” was the only predictor of survival 
when adjusting for all covariates. Conclusions: NSS status is a possible outcome measure in ALS to 
investigate short-term efficacy of treatments of ALS. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease ending in 
death or severe disability in 3-5 years from symptom onset (1). Time to death and functional decline 
are the preferred measures to assess the prognosis of the disease and the effects of treatments. The 
guideline issued by the European Medicines Agency (EMA) on the clinical investigation of 
medicinal products for the treatment of amyotrophic lateral sclerosis (ALS) (2) requires either 
survival time  or ALS Functional Rating Scale in its original (ALS-FRS) (3) or revised version 
(ALS-FRS-R) [4] to be used as primary outcome measure. Secondary measures include the 
assessment of functional ability, muscle strength, respiratory function and quality of life. 
The ALS-FRS-R (3) is the most widely used instrument to measure the progression of the disease 
and the degree of functional impairment in ALS. The ALS-FRS-R has been confirmed highly 
reliable (5, 6) and is accepted as a valuable outcome measure in clinical trials (7). However, the 
decline measured by the ALS-FRS-R has been found non-linear in a substantial number of patients 
(8). Furthermore, the scale is insensitive to change (9) particularly in patients with advanced disease 
(10). This limitation led investigators to suggest collapsing the five level ratings into three levels 
(11) or to add new items to measure abilities in patients with advanced disease (12). Then, in spite 
of a consensus among clinicians that a change of 20% or greater in the slope is a surrogate of a 
clinically significant functional deterioration (13), the total score of the scale (the measure used in 
clinical trials as a marker of functional impairment) does not indicate which functions are lost and, 
most importantly, if the patient lost his/her self-sufficiency. 
Markers of self-sufficiency (swallowing, cutting food and handling utensils, or walking), as 
measured by the ALS-FRS-R scale, were recently used as primary outcomes in two randomized 
trials assessing the efficacy of Acetyl-L-carnitine and Lithium in ALS (14, 15). Non self-sufficiency 
(NSS) was defined as a score of 2 or lower on at least one of the three ALSFRS-R items over 12 
months. However, this measure requires validation. On this background, the main aim of the present 
study was to assess the sensitivity to change of NSS status and of each of its three items separately. 
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More specifically, we decided to (i) describe the risk of a patient with ALS to become non self-
sufficient (NSS) during follow-up, (ii) verify whether NSS status was associated with the total 
ALS-FRS-R score and to other measures of functional disability, (iii) identify if the ALS-FRS-R 
items indicating self-sufficiency are prognostic factors for survival of ALS patients, and (iv) among 
items of ALS-FRS-R, which items are prognostic indicators. 
 
Material and Methods 
Patients 
Included were patients enrolled in the placebo arm of the randomized trial on Acetyl-L-carnitine 
(14), in the subtherapeutic arm (pseudo placebo) of the randomized trial on Lithium (15), and in the 
context of an observational study of the outcome of ALS in a tertiary center. Patients were accepted 
for the analysis only if self-sufficient at baseline (time of inclusion) in the study. 
Follow-up 
Patients were followed for 48 weeks or until death, whichever came first. If possible, vital status 
was investigated for up to 68 months in patients who were still alive at the end of the trial. 
Data collection 
The following data were recorded from the trial files: Age, sex, site of onset (spinal vs. bulbar), 
body mass index (BMI) at baseline, forced vital capacity (FVC) at baseline, 24, 36 and 48 weeks, 
and ALS-FRS-R scale at baseline and at 4, 12, 24, 36 and 48 weeks, and NSS status (ie, a score of 2 
or lower on at least one of the ALS-FRS-R items for swallowing, cutting food and handling 
utensils, or walking) at baseline, and at 4, 12, 24, 36, and 48 weeks. 
Ethics 
The ethics committees of the participating centres approved both trials. As anonymized data were 
obtained from the trial databases, no additional ethical approval was required. 
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Statistical analysis 
Descriptive statistics are given for all the baseline variables, with frequency, percentages, medians 
and interquartile range(IQR) as appropriate. The NSS status and the ALS-FRS-R score are 
presented at baseline and at each time point during follow-up. NSS and demographic and main 
clinical variables were correlated using the Mann-Whitney, Chi-square or Fisher exact test where 
appropriate. The change of NSS status over time has been assessed using actuarial methods. The 
association between each variable at baseline and NSS status during follow-up was tested with 
Cox’s proportional hazards function models. Survival was assessed using Kaplan-Meier curves. The 
association between NSS status at 4 weeks and survival was evaluated using the Log-rank test. The 
prediction of survival based on NSS status at 4 weeks was tested using univariate and multivariate 
models, the latter including age at inclusion, sex, site of onset, BMI, FVC and ALSFRS-R at 
baseline as covariates. Each item of the ALS-FRS-R scale was assessed separately in univariate and 
multivariate Cox models. Abnormal values scored 2 or less for each item, except for item 12 
(respiratory insufficiency) for which abnormal values were any score lower than 4. Statistical 
significance was set at the 5% level (p<0.05). Statistical analyses were performed using the SAS 
statistical package (version 9.2; SAS Institute, Cary, NC). 
 
Results 
The sample included 82 patients (53 men and 29 women) aged 33 to 76 years (median 61.5 years, 
IQR 54.7-68.0) (Table 1). Patients with bulbar-onset ALS were 30.5%. At study entry, disability 
was modest and nutritional status was excellent in most cases. 
Loss of self-sufficiency during follow-up 
Twenty-two patients (39.0%) became NSS at 4 weeks and 72 (87.8%) at the end of follow-up. 
There was no difference between SS and NSS patients as regards age (p=0.27), sex (p=0.88) and 
site of onset (p=0.71). The cumulative time-dependent probability of remaining SS decreased with 
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time and was 19.9% at 24 weeks and 7.8% at 48 weeks (Figure 1). None of the baseline variables 
was associated with NSS status during follow-up (Table 2). 
Association between NSS status and other measures of functional disability  
As indicated in Table 3, when comparing at each time point functional status of NSS and SS 
patients, the ALS-FRS-R total score was consistently lower in NSS than in SS subjects. In contrast, 
there was no association between NSS status and FVC at 24 and 36 weeks. When comparing at 
each time the clinical status of SS patients to that of subjects who became NSS at 4 weeks, similar 
results were obtained for ALS-FRS-R total score. In this subpopulation, an association was found 
between NSS and FVC at 24, 36 and 48 weeks. 
Loss of self-sufficiency and survival 
During follow-up, 34 subjects died (41.5%), 11 within the first 48 weeks. As compared to SS 
patients, individuals becoming NSS at 4 weeks had a 2.28 increased risk to die during follow-up 
(95% confidence interval, CI 1.15-4.59). The median survival time in NSS patients was 23.6 
months (95% CI 8.2-40.7) for NSS and 27.9 months (95% CI 21.8-54.4) in SS individuals (p=0.02, 
Figure 2). NSS status at 4 weeks predicted survival (HR 2.77, 95% CI 1.26-6.15), even after 
adjustment for ALS-FRS-R total score, age, sex, site of onset, BMI, and FVC (Table 5). 
NSS status during the entire follow-up (time varying covariate) was also assessed as an explanatory 
variable for survival. The association was not statistically significant both in univariate and in 
multivariate analysis (HR 2.7 95% CI 0.60-12.34, p=0.20) after adjusting for the same covariates 
(Table 5).  
Association between survival and each ALS-FRS-R item 
On univariate analysis, none of the 12 items of the ALS-FRS-R scale, if found abnormal, was 
associated with death (Table 6). When adjusting for all ALS-FRS-R items (multivariate model 1), 
“walking” was the only item predicting survival. Another item (“cutting food and handling 
utensils”) was of borderline significance (p=0.08).  
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Discussion 
In this study, NSS status was found to be sensitive to the change of the clinical state of ALS 
patients as being associated with the entire ALS-FRS-R score and to other measures of functional 
disability. NSS at 4 weeks also predicted survival with a significant difference in the median 
survival time between SS and NSS patients, which was confirmed after adjustment on confounding 
factors. One of its components (ie, walking) was the only independent prognostic predictor for 
survival. Another component (cutting food/handling utensils) resulted of borderline significance. 
We can hypothesize that a modification in the occurrence of NSS (mostly represented by lack of 
ambulation) could result in a modification in the survival of ALS patients. Hence, NSS status can be 
proposed as a surrogate endpoint in ALS phase II and III trials. It has the advantage of being by 
itself clinically relevant, an excellent quality for a surrogate marker. Then, its interpretation is easy 
in contrast with other score-based outcomes. 
As indicated in this study, the outcome of ALS measured by loss of self-sufficiency is rapid 
(subjects remaining SS during time being 61.0% at 4 weeks and 19.9% at 24 weeks). Thus, NSS 
status can be used as a variable with high probability of occurrence within the time limits of a 
clinical trial.  
The association between NSS and the total ALS-R score and, to some extent the FVC score, further 
confirms the role of self-sufficiency as a marker of disease progression. When we compared NSS 
status to a subscore of the ALS-FRS-R scale (calculated excluding the three measures of self-
sufficiency), the association remained unchanged (data not shown).  
Interestingly, except for  walking and, to some extent, cutting food/handling utensils, none of the 
other scale items were associated with survival. This reinforces the clinical relevance of the NSS 
status as a prognostic predictor and seems to explain that the prognostic significance of the ALS-
FRS-R scale is mostly driven by these two subscales. 
Among the three markers of self-sufficiency, swallowing was not found to predict survival. This 
can be explained by the small number of cases with dysphagia at 4 weeks (n=6). The same holds 
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true for other bulbar signs (except for speech), and signs of respiratory insufficiency. Most patients 
included in this study had modest disability and excellent nutritional status at 4 weeks. Thus, the 
prognostic role of dysphagia cannot be entirely excluded here because of the small sample size. 
The lack of association between loss of self-sufficiency and relevant demographic and clinical 
variables (except for age) seems to support the robustness of this outcome measure, which is 
independent from the main prognostic predictors. Then, the detection of NSS as an early (4-week) 
predictor of mortality supports the role of self-sufficiency as a valuable end-point when testing the 
early effects of an investigational treatment. 
Alternative measures of disease progression have been recently developed (16, 17). However, 
compared to these markers, loss of self-sufficiency is a simple measure based on the assessment of 
selected functions having strong impact on fine and gross motor activities and on nutritional state. 
Compared to the entire ALS-FRS-R scale, this marker of disease progression can be used on an 
individual basis to identify potential responders to experimental treatments. 
The study has limitations that must be highlighted. First of all, only one of the three items seems an 
independent predictor of disease progression and survival. The third component (swallowing) may 
deserve further investigation by examining patients in late stages of the disease. Second, we tested 
NSS status (the sum of three subscores of the ALS-FRS-R scale) against the total ALS-FRS-R 
score. An association may be thus expected as the two scores are not totally independent. However, 
other independent measures of disease severity, like FVC and death, have been found to be 
significantly associated with loss of self-sufficiency. Third, the sample size is small and may 
prevent the detection of otherwise significant associations. A larger, more representative and 
independent ALS population should be evaluated to confirm the validity of NSS status as a 
prognostic marker. Fourth, survival of patients after the end of the trials was tentatively monitored, 
but was not possible for all patients. Firth, NSS status was found to predict survival at 4 weeks but 
not when considered along the entire follow-up. As the adjusted hazards ratio was 2.77 at 4 weeks 
and 2.70 for NSS as time varying covariate, the non-significant risk might be explained by a lack of 
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power of this analysis. A study in a larger sample is again needed to confirm or disprove the present 
findings. 
 
Conclusions 
NSS status is a promising outcome measure in randomized trials in ALS patients, which could be 
used as a primary end-point to investigate short-term efficacy of investigational drugs and other 
treatments. ALS-FRS-R scale is still a recommended instrument to monitor disease progression 
and, as such, it cannot be at present replaced. However, further studies are needed in large and 
representative ALS populations to verify whether some subscales or individual items should be 
removed from the scale as being non-influential in marking the outcome of ALS. 
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Table 1. Demographical and clinical characteristics of the sample at baseline (n=82) 
Variables 
 
Median  
or frequency 
Interquartile range or 
percentage 
Quantitative    
Age  61.5 54.7-68.0 
ALSFRS-R score  42.0 39.0-44.0 
FVC score (% of 
predicted) 
 84.9 77.7-97.4 
BMI  24.5 22.1-26.2 
Qualitative    
Sex Female 29 35.4 
 Male 53 64.6 
Site of onset Bulbar 25 30.5 
 Spinal 57 69.5 
BMI: Body mass index; FVC: Forced vital capacity. 
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Table 2. NSS status during follow-up and baseline characteristics. Univariate Cox analysis 
Variable      HR      95%CI p-value 
Sex Male 1.00 (ref)     
 Female 1.26  0.78 - 2.05 0.34 
Site of onset Spinal 1.00 (ref)     
 Bulbar 1.10 0.67 - 1.82 0.70 
Age 5 year increase 1.03 0.92 - 1.15 0.64 
FVC (% of 
predicted) 
10% increase 0.97 0.81 - 1.16 0.71 
BMI Class Malnutrition 1.10 0.15 - 8.04 0.64 
 Normal 1.00 (ref)     
 Overweight 1.35 0.81 - 2.25  
 Obese 1.48 0.58 - 3.74  
 
NSS: Non self-sufficient; HR: Hazards ratio; 95% CI: 95% Confidence interval;                                                 
BMI: Body mass index: (i) Malnutrition: BMI <18.5 if age <70 years orBMI<21 if age≥70 years; 
(ii) Normal: 18.5≤BMI<25 if age <70 years or 21≤BMI<27 if age ≥70 years; (iii) Overweight: 
25≤BMI<30if age <70 years or 27≤BMI<30 if age ≥70 years; (iv) Obesity:BMI≥30, FVC: Forced 
vital capacity. 
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Table 3. ALS-FRS-R and FVC scores in SS and NSS patients at various time points during  follow-up 
Timepoint Scale/Measure of 
disease progression 
Self-
sufficiency 
N Median IQR p-value 
4 weeks ALS-FRS-R (total) SS 50 42.0 40.0 - 44.0 <0.0001 
  NSS 32 36.5 33.0 - 39.5  
         
12 weeks ALS-FRS-R (total) SS 30 42.0 40.0 - 44.0 <0.0001 
  NSS 50 35.5 29.0 - 39.0  
         
24 weeks ALS-FRS-R (total) SS 15 41.0 39.0 - 44.0 <0.0001 
  NSS 53 34.0 28.0 - 37.0  
 FVC (% predicted) SS 9 78.0 73.6 - 82.0 0.1316 
  NSS 34 68.7 58.8 - 80.9  
         
36 weeks ALS-FRS-R (total) SS 10 40.0 39.0 - 44.0 0.0002 
  NSS 45 32.0 25.0 - 36.0  
 FVC (% predicted) SS 8 77.5 68.8  86.5 0.0574 
  NSS 26 63.2 48.6 - 73.0  
         
48 weeks ALS-FRS-R (total) SS 4 41.0 38.0 - 43.5 0.0040 
  NSS 40 27.5 21.0 - 32.5  
 FVC (% predicted) SS 3 78.0 78.0 - 92.0 0.0435 
  NSS 24 48.5 40.5 - 71.0  
 
SS: Self-sufficient; NSS: Non self-sufficient; FVC: Forced vital capacity; IQR: interquartile range. 
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Table 4.  ALS-FRS-R and FVC scores at various time points for SS patients and patients who 
became NSS at 4 weeks 
Time point Scale/Measure of 
disease progression 
Self-
sufficiency 
N Median IQR p-value 
4 weeks ALS-FRS-R (total) SS 50 42.0 40.0 - 44.0 <0.0001 
  NSS 32 36.5 33.0 - 39.5  
         
12 weeks ALS-FRS-R (total) SS 30 42.0 40.0 - 44.0 <0.0001 
  NSS 29 31.0 26.0 - 37.0  
         
24 weeks ALS-FRS-R (total) SS 15 41.0 39.0 - 44.0 <0.0001 
  NSS 23 28.0 19.0 - 36.0  
 FVC (% predicted) SS 9 78.0 73.6 - 82.0 0.0182 
  NSS 14 63.3 45.5 - 71.0  
         
36 weeks ALS-FRS-R (total) SS 10 40.0 39.0 - 44.0 0.0011 
  NSS 17 27.0 23.0 - 33.0  
 FVC (% predicted) SS 8 77.5 68.8 - 86.5 0.0123 
  NSS 10 55.8 36.2 - 66.0  
         
48 weeks ALS-FRS-R (total) SS 4 41.0 38.0 - 43.5 0.0189 
  NSS 13 26.0 21.0 - 31.0  
 FVC (% predicted) SS 3 78.0 78.0 - 92.0 0.0347 
  NSS 9 46.0 42.4 - 49.0  
 
SS: Self-sufficient; NSS: Non self-sufficient; FVC: Forced vital capacity; IQR: interquartile range. 
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Table 5. Association between NSS status and survival in univariate and multivariate analysis 
 
NSS: Non self-sufficient; BMI: Body mass index; FVC: Forced vital capacity; HR: Hazards ratio;  
95% CI: 95% Confidence interval. 
Variable      HR      95%CI p-value 
 NSS at 4 
weeks 
Univariate 2.28 1.13 - 4.59 0.021 
Multivariate (after adjustment 
on age, gender, bulbar form, 
BMI, FVC, ALSFRS-R) 
2.77 1.26 - 6.15 0.013 
       
NSS during 
the  entire 
follow-up 
Univariate 2.81 0.64 - 12.42 0.173 
Multivariate (after adjustment 
on age, gender, BMI, FVC, 
ALSFRS-R) 
2.70 0.60 - 12.34 0.202 
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Table 6. Association between abnormal ALS-FRS-R items  and survival 
               
Variables 
 
  Univariate analysis 
 
Multivariate analysis model 1 
 
Multivariate analysis model 2 
  Hazard 
Ratio 95%CI p-value 
 
Hazard 
Ratio 95%CI p-value 
 
Hazard 
Ratio 95%CI p-value 
ALS-FRS-R item 
Abnormal value 
(%)* 
            
 
1. Speech 16 (19.5) 
 
0.68 0.26-1.80 0.44 
 
0.58 0.17-1.97 0.38 
 
0.30 0.07-1.31 0.11 
 
2. Salivation 7 (8.5) 
 
ne** 
          
 
3. Swallowing 6 (7.3) 
 
1.11 0.26-4.70 0.88 
 
1.06 0.16-7.10 0.96 
 
0.85 0.10-7.03 0.85 
 
4. Handwriting 9 (11.0) 
 
1.56 0.60-4.10 0.36 
 
2.07 0.48-8.93 0.33 
 
2.55 0.53-12.30 0.24 
 
5. Cutting food and handling ustensils 15 (18.3) 
 
1.77 0.79-3.96 0.16 
 
2.92 0.64-13.33 0.17 
 
4.88 0.84-28.48 0.08 
 
6. Dressing and hygiene 23 (28.1) 
 
1.47 0.71-3.06 0.30 
 
0.59 0.15-2.28 0.59 
 
0.66 0.13-3.26 0.60 
 
7. Turning in bed and adjusting bed 
clothes 14 (17.1) 
 
1.29 0.57-2.88 0.53 
 
0.55 0.15-2.02 0.37 
 
0.40 0.10-1.66 0.21 
 
8. Walking 19 (23.2) 
 
2.08 0.99-4.36 0.05 
 
2.78 1.08-7.20 0.03 
 
2.84 1.04-7.73 0.04 
 
9. Climbing stairs 46 (56.1) 
 
1.13 0.56-2.29 0.74 
 
0.95 0.39-2.28 0.91 
 
1.49 0.57-3.92 0.42 
 
10. Dyspnea 6 (7.3) 
 
1.59 0.55-4.55 0.39 
 
0.97 0.26-3.58 0.96 
 
1.06 0.28-4.00 0.93 
 
11. Orthopnea 0 (0.0) 
 
ne*** 
          
 
12. Respiratory insufficiency 17 (20.7) 
 
0.69 0.28-1.69 0.42 
 
0.79 0.31-2.06 0.63 
 
0.70 0.22-2.22 0.55 
               Male sex 
  
1.28 0.62-2.67 0.50 
     
1.47 0.57-3.81 0.43 
               Bulbar site of onset 
  
1.10 0.52-2.34 0.81 
     
4.06 1.22-13.46 0.02 
               BMI categories 
    
0.23 
       
0.08 
 
Malnutrition 
  
5.07 0.65-39.82 
      
17.97 1.46-221.34 
 
 
Normal 
  
1.0 
       
1.0 
  
 
Overweight 
  
0.71 0.32-1.57 
      
0.69 0.25-1.96 
 
 
Obese 
  
1.71 0.50-5.83 
      
2.61 0.61-11.03 
 
               
 
  
   
     
   
20. 
 
 
 
Age (for 5 years increase) 
 
1.05 
 
0.88-1.24 
 
0.60 
 
0.99 
 
0.79-1.25 
 
0.95 
               FVC (for 10 units increase)     0.88 0.66-1.16 0.35           0.88 0.59-1.31 0.52 
              
 
 
* Abnormal values scored 2 or less for each item, except for item 12 (respiratory insufficiency) for which abnormal values were any score lower than 4;  
95% CI : 95% Confidence interval ; ne: not estimated because   ** no deaths recorded,   *** no patient with abnormal values; BMI: Body mass index,  
FVC: Forced vital capacity. 
 
 
21. 
 
 
 
 
Figure 1. Cumulative time-dependent probability of retaining self-sufficiency in the entire 
 sample (n=82) 
  
22. 
 
 
 
Figure 2. Cumulative time-dependent survival in non self-sufficient (red) vs. self-sufficient  
 patients (blue) at 4 weeks (p=0.0172)  
 
